FIG 3.
(A) Effects of therapeutic drug concentrations of selected anti-HIV drugs (Table 3 lists the drug abbreviations) on the letermovir EC50 value for inhibition of HCMV replication. (B) Effects of a clinically relevant letermovir dose on the EC50 values of the indicated anti-HIV drugs for inhibition of HIV-1 replication. The EC50 values were determined for the indicated fixed-dose drug combinations and for single-drug dilutions. EC50 fold changes of the indicated drug combinations were calculated as outlined in Materials and Methods (dashed line: no effect/inertism; for consensus terminology for two-agent combined action concepts, see reference 38). Each data point represents the average of the results of three independent experiments and is shown with the standard deviation.